Oslo Pensjonsforsikring AS Invests $950,000 in Pfizer Inc. $PFE

Oslo Pensjonsforsikring AS bought a new stake in Pfizer Inc. (NYSE:PFE) in the first quarter, Holdings Channel.com reports. The firm bought 33,840 shares of the biopharmaceutical company’s stock, valued at approximately $950,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Vermillion Wealth Management Inc. lifted its stake in Pfizer by 19.4% in the 1st quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock worth $66,000 after purchasing an additional 382 shares in the last quarter. Triad Wealth Partners LLC grew its position in shares of Pfizer by 1.9% in the fourth quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock valued at $510,000 after purchasing an additional 386 shares in the last quarter. Eagle Capital Management LLC increased its holdings in shares of Pfizer by 0.3% in the first quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock valued at $3,554,000 after purchasing an additional 390 shares during the last quarter. ETF Store Inc. increased its holdings in shares of Pfizer by 3.8% in the fourth quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock valued at $272,000 after purchasing an additional 396 shares during the last quarter. Finally, Delta Financial Advisors LLC lifted its position in Pfizer by 1.6% during the first quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company’s stock worth $709,000 after buying an additional 398 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer could benefit from strength in key non-oncology drugs, with Eliquis and Vyndaqel expected to post better Q2 sales, which may help offset declines elsewhere in the portfolio. What to Watch in Pfizer’s Non-Oncology Portfolio This Earnings Season
• Positive Sentiment: Pfizer is drawing interest as a potential winner in the large weight-loss drug market, supporting longer-term growth expectations if it can compete successfully. Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market?
• Neutral Sentiment: Pfizer remains one of the more watched healthcare names among investors, suggesting the stock may see ongoing trading interest ahead of earnings and new updates. Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
• Neutral Sentiment: Recent commentary compared Pfizer with other sub-$50 stocks, but the note was mainly a general screening piece rather than a company-specific catalyst. 1 Stock Under $50 to Target This Week and 2 We Question
• Negative Sentiment: Pfizer faces new international patent lawsuits from Arbutus Biopharma and Genevant Sciences over its mRNA COVID-19 vaccines, creating potential damage claims and injunction risk. Pfizer (PFE) Faces New International Patent Lawsuits Over Covid 19 Vaccine
• Negative Sentiment: COVID-related product sales are expected to decline, which may weigh on quarterly results and reinforce concerns about shrinking pandemic-era revenue streams. What to Watch in Pfizer’s Non-Oncology Portfolio This Earnings Season

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. Citigroup lifted their price target on Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a report on Wednesday, April 29th. HSBC cut shares of Pfizer from a “buy” rating to a “hold” rating and lowered their price target for the company from $32.00 to $28.00 in a research report on Monday, July 6th. JPMorgan Chase & Co. cut their price objective on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a research report on Wednesday, July 8th. Finally, Guggenheim reduced their target price on shares of Pfizer from $36.00 to $35.00 and set a “buy” rating on the stock in a research note on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $28.50.

Pfizer Stock Performance

NYSE:PFE opened at $24.91 on Wednesday. Pfizer Inc. has a fifty-two week low of $23.11 and a fifty-two week high of $28.75. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The company has a 50 day moving average price of $25.17 and a 200 day moving average price of $26.18. The stock has a market capitalization of $141.97 billion, a P/E ratio of 19.02 and a beta of 0.35.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. During the same quarter in the previous year, the company earned $0.92 earnings per share. The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts forecast that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. The ex-dividend date is Friday, July 24th. Pfizer’s payout ratio is currently 131.30%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.